Biomarker, detection reagent or kit suitable for eight common malignant tumors and application of biomarker, detection reagent or kit
By screening RNA characteristic molecules in blood exosomes to construct a pan-cancer classification model, the problem of lack of reliable biomarkers and classification effectiveness in the prior art was solved, and high recognition and accuracy of 8 common malignant tumors were achieved. Early detection, providing non-invasive solutions.
Patent Information
- Application Number
- CN202410931244.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-07-08
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art lacks reliable pan-cancer biomarkers and individual cancer markers, and lacks systematic algorithms and verification models for evaluating the effectiveness of biomarker classification, making it difficult to achieve rapid screening of early tumors.
By screening 12 RNA characteristic molecules (ETR.sig) in blood exosomes, a pan-cancer classification model based on TaqMan qPCR technology was constructed, and non-invasive biomarkers were constructed to achieve early pan-cancer Test.
Achieve high recognition and accuracy of 8 common malignant tumors, providing a non-invasive solution for early-stage pan-cancer detection, highlighting the value of ETR.sig in a variety of human cancer detections.
Smart Images

Figure CN118910254A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of tumor screening, and specifically to biomarkers, detection reagents or kits applicable to 8 common malignant tumors and their applications. Background Art
[0002] Cancer, as a prevalent global health problem, is one of the leading causes of death worldwide. Global cancer cases are expected to surge to approximately 28 million by 2040, highlighting the urgency of the need for comprehensive strategies in cancer prevention, diagnosis, and treatment. Epidemiological studies have shown that patients diagnosed with cancer at an early stage exhibit superior clinical outcomes than those diagnosed at a late stage. Therefore, there is an urgent need for early screening and diagnosis, driving clinical scientists to continuously explore the field of reliable cancer biomarkers. Despite advances in the scientific community, the current cancer diagnostic landscape still relies heavily on a combination of laboratory tests and imaging technologies. Although this two-pronged approach provides valuable insights, it not only imposes an economic burden on patients, but also fails to replace the irreplaceable role of pathological examination in the diagnostic paradigm.
[0003] Extracellular vesicles, including exosomes, can serve as an alternative or complement to liquid biopsies to enhance diagnostic performance. Mechanistically, active cells continuously release exosomes, which contain DNA, RNA, and protein components, thereby providing clinically relevant diagnostic information. Recent studies have increasingly utilized comprehensive transcriptomics approaches, such as RNA sequencing (RNA-seq), to study the content of RNA in exosomes during physiological and pathological processes, such as cerebrospinal fluid, plasma, and urine observed in various samples. In the field of tumor diagnosis, several studies have successfully used these technologies to achieve good results, bringing new possibilities for cancer diagnosis and treatment.
[0004] In view of this, the present invention is proposed. Summary of the invention
[0005] 1. Technical issues to be resolved
[0006] In view of the shortcomings of the prior art, the present invention provides markers and detection methods suitable for risk prediction of 8 common malignant tumors, solving the current problem of lack of reliable pan-cancer biomarkers and corresponding markers for individual cancers. In addition, there is currently a lack of systematic algorithms and validation models for evaluating the classification efficacy of selected biomarkers. Therefore, the present invention proposes a method based on 12 RNA signature molecules (Exosomal tumor RNA signatures, ETR.sig) screened in pan-cancer blood exosomes, including: ALB, FCER1G, KRT18, LCN2, PPDPF, SLC9A3R2, AGO2, CKS2, MALAT1, RAB32, S100A9 and UBE2Q2 genes, to construct a pan-cancer classification model. This model provides a new solution for the rapid screening of tumors in the population.
[0007] (II) Technical solution
[0008] To achieve the above objectives, the present invention is implemented through the following technical scheme: a marker suitable for predicting the risk of 8 common malignant tumors, which is based on blood exosome TaqMan qPCR technology and 12 screened RNA characteristic molecules ETR.sig, which can be used as a non-invasive biomarker for early pan-cancer detection.
[0009] The present invention also provides a method for detecting markers suitable for predicting the risk of 8 common malignant tumors, which specifically comprises the following steps:
[0010] S1. Screening of RNA signature molecules in pan-cancer blood exosomes based on RNA sequencing;
[0011] S2. Screening of RNA signature molecules in pan-cancer blood exosomes based on TaqMan qPCR;
[0012] S3. Construct a pan-cancer classification model based on characteristic molecules screened by TaqMan qPCR.
[0013] Preferably, the screening of RNA characteristic molecules in pan-cancer blood exosomes based on RNA sequencing in step S1 specifically comprises the following steps:
[0014] A1. Construct a dataset including exoRbase database and 818 blood exosome RNA sequencing data summaries, covering eight different cancer types. Specifically, the dataset includes a total of 194 healthy control samples, exoRbase = 118, CNP0005119 = 31, CNP0002099 = 28, CNP0000926 = 17, ensuring comprehensive and diverse representation in various cancer types;
[0015] A2, the quality control of raw fastq data was performed using trim-galore alignment, sorting was performed using SAMtools, and featureCounts was used for final gene expression quantification;
[0016] A3. In the blood exosome RNA-seq data, the identification of differentially expressed genes DEGs was performed according to the criteria of |log2FC|>1 and P value <0.05. Subsequently, the DESeq2, limma and edgeR packages were used to apply the threshold of P value <0.05 and |log2FC|>1 to determine DEGs in the whole genome RNA-seq cohort in TCGA. The results of differential expression analysis were visualized by bar graphs using ggplot2, and violin plots were used to visualize the gene expression differences according to TaqMan qPCR data.
[0017] A4. The UpSetR package was used to perform intersection analysis and visualization of DEGs in blood exosome exoRNA-seq data in various tumors. In order to determine the gene set suitable for pan-cancer classification, cancer exoRNA-seq data were integrated, and differential expression analysis was performed between tumor and control tissues. DEGs with P value < 0.01 and fold change (FC) ≥ 1.4 or ≤ -1.6 were screened. Subsequently, univariate logistic regression analysis was used to screen genes for building classification models, and genes with P value < 0.05 were retained. In addition, LASSO analysis was used, and 1000 repeated 10-fold cross-validation CVs were performed to refine the selection of feature gene sets;
[0018] A5. Use machine learning technology to select the best gene set from LASSO analysis, and use stratified random sampling method to divide the exoRNA-seq cohort into a training set and a validation set with a ratio of 7:3. The training set is used to build a random forest RF classification model, and the validation set is used to evaluate the classification performance. The effectiveness of the model is evaluated by calculating the area under the curve (AUC) value of the receiver operating characteristic (ROC) curve. Finally, the best gene set is determined by comparing the AUC value of the model in the validation set.
[0019] Preferably, in step A1, exoRbase provides samples of patients with breast cancer (BRCA, n=140), colorectal cancer (COAD, n=35), hepatocellular carcinoma (LIHC, n=112), ovarian cancer (OV, n=30) and pancreatic adenocarcinoma (PAAD, n=164). In addition, the exoRNA-seq data of lung adenocarcinoma (LUAD, n=83), renal clear cell carcinoma (KIRC, n=29) and prostate adenocarcinoma (PRAD, n=31) with access numbers CNP0005119, CNP0002099 and CNP0000926 under CNGBdb in the study.
[0020] Preferably, the entire process is implemented using the tidymodels and pROCR software packages.
[0021] Preferably, the screening of RNA characteristic molecules in pan-cancer blood exosomes based on TaqMan qPCR in step S2 specifically includes the following steps:
[0022] B1. Selection of experimental participants: The inclusion criteria for patients were as follows: (1) age > 18 years; (2) clear pathological diagnosis; (3) no anticancer treatment before blood collection; (4) no other history of cancer; (6) signed informed consent. The inclusion criteria for the healthy control group were as follows: (1) age > 18 years; (2) underwent a health check and were considered as asymptomatic and healthy. The exclusion criteria were as follows: (1) previously diagnosed with a tumor; (2) received ablation therapy; (3) had other malignant tumors.
[0023] B2. Sample collection and processing: Patients signed informed consent on the first day of admission, and fasting peripheral blood was collected the next morning. Samples were stored at 4°C and transported to the laboratory on ice. Blood samples were coagulated at room temperature for at least 30 minutes and up to 2 hours. Then, all samples were centrifuged at 1600×g for 15 minutes, serum was separated, and the supernatant was collected in 1.5ml centrifuge tubes and numbered. Serum samples were immediately frozen at -80°C until further processing.
[0024] B3. Isolation and RNA extraction of blood-derived exosomes: Blood-derived exosomes were isolated and RNA was extracted using the exoRNeasy Midi / Maxi Kit. The specific steps are as follows: Buffer XBP was added to the sample at a ratio of 1:1. Mix by inversion 5 times to ensure thorough mixing. The mixture was then added to the exoEasy spin column and centrifuged at 500×g for 1 minute. (Note: If there is residual liquid on the membrane, further centrifuge at 5000×g for 1 minute to ensure that all liquid passes completely through the membrane.) Next, 3.5 ml of BufferXWP was added and centrifuged at 5000×g for 1 minute to wash the column and remove residual buffer. The filtrate and bottom collection tube were discarded, and the spin column was transferred to a new collection tube. Then, 700 μl of QIAzol was added to the column membrane and centrifuged at 5000×g for 5 minutes to collect the lysate and then completely transferred to a 2 ml tube. The lysate in the tube was gently mixed and incubated at room temperature (15-25°C) for 5 minutes. Then, add 90 μl of chloroform, cap the tube tightly, and mix vigorously for 15 seconds. Incubate at room temperature for 2-3 minutes. Then place the tube in a pre-refrigerated centrifuge and centrifuge at 12,000 × g for 15 minutes at 4°C. Transfer the supernatant to a new 2.0 ml tube (be careful to avoid aspirating the organic phase). Add an equal volume of ethanol and invert several times. Then, add 700 μl of the mixture to the RNeasy MinElute spin column in a 2 ml collection tube and incubate for 2 minutes, then cap the tube. Centrifuge at 12,000 × g for 1 minute at room temperature, and discard the filtrate. Repeat this step until all the mixture is used. Then, add 700 μl of Buffer RWT to the RNeasy MinElute spin column, cap the tube, centrifuge at 12,000 × g for 1 minute at room temperature, and discard the filtrate. Add 500 μl of Buffer RPE to the RNeasy MinElute spin column, cap the tube, centrifuge at 12,000 × g for 1 minute at room temperature, and discard the filtrate. Add 500 μl of Buffer RPE to the RNeasy MinElute spin column, cap the tube, centrifuge at 12,000 × g for 2 minutes at room temperature, and discard the filtrate. Place the RNeasy MinElute spin column in a new 2.0 ml collection tube, centrifuge at 12,000 × g for 5 minutes at room temperature, and discard the filtrate and the bottom 2.0 ml collection tube. Place the RNeasy MinElute spin column in a new 1.5 ml tube and add 14 μl of pre-heated RNase-free water to the center of the silica membrane. Cap the tube and centrifuge at 12,000 × g for 1 minute at room temperature. Discard the RNeasy MinElute spin column and collect the purified RNA solution in a 1.5 ml tube.Transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA) and western blotting (WB) were used to identify the isolated exosomes.
[0025] B4. Reverse transcription of blood-derived exosome RNA: cDNA was generated using a two-step reverse transcription process using the Takara RR047A kit, which included gDNA digestion and cDNA strand synthesis. The reaction components and procedures for each step are as follows. Step 1: gDNA digestion. In a 13μl reaction mixture, add 2.0μl of 5×gDNAEraser buffer, 1.0μl of gDNAEraser, and 10μl of total RNA and mix gently. The reaction was performed in a PCR instrument with the program set to 42°C for 2 minutes and then maintained at 4°C. Step 2: Reverse transcription. In a 20μl reaction mixture, add 13.0μl from the first step reaction mixture, 1.0μl of PrimeScript RT Enzyme Mix I, 1.0μl of RT Primer Mix, 4.0μl of 5×PrimeScript Buffer 2 (for real-time), and 1.0μl of RNase-free dH2O and mix gently. The reaction was performed in a PCR instrument with the program set to 37°C for 15 min, followed by an incubation at 85°C for 5 s and a final hold at 4°C.
[0026] B5. Primer design and synthesis of detection targets: The target gene sequence was retrieved using the Ensembl database, and qPCR primers were designed using the NCBI primer design tool website (https: / / www.ncbi.nlm.nih.gov / tools / primer-blast / index.cgi?LINK_LOC=BlastHome). Primer design criteria included a melting temperature (Tm) in the range of 55-65°C, a GC content in the range of 40%-60%, a minimum number of mismatches, and good specificity.
[0027] B6. Primer verification: RNA was extracted from cancer / tumor adjacent tissues or cell lines and reverse transcribed into cDNA templates. Exosomal RNA of the sample to be verified was also prepared and reverse transcribed into cDNA. The melting temperature (Tm) value of each pair of primers was analyzed, and 3-4 gradient annealing temperature values were set. The cDNA of cancer / tumor adjacent tissues or cell lines was used as a template, and diluted primers were used as amplification primers. PCR amplification was performed at different gradient annealing temperatures (35 cycles) using TB Green II enzyme. The PCR program was as follows: pre-denaturation at 95°C for 30 seconds; denaturation at 95°C for 5 seconds; annealing at 58°C, 59°C or 60°C for 30 seconds; extension at 72°C for 15 seconds; final extension at 72°C for 5 minutes. The reaction mixture included 2μl cDNA, 5μl 2×TB Green, 0.4μM / 0.4μM primers F / R (10μM), and 2.2μl ddH2O. Mix the PCR products with DNA loading buffer and verify their size by 1.5% agarose gel electrophoresis to confirm the expected amplification product size and primer specificity and determine the optimal annealing temperature. Select primers with a single amplification product and the expected fragment size. Use cancer / tumor adjacent tissue or cell line cDNA as template and blood-derived exosome cDNA as template using TB-based Premix Ex Taq TM The melting curve of the primers was determined by qPCR of the dye. The PCR program was as follows: pre-denaturation at 95°C for 30 seconds; denaturation at 95°C for 5 seconds; annealing at the selected optimal annealing temperature for 34 seconds; raising the temperature to 95°C for 15 seconds, annealing at the selected optimal annealing temperature for 1 minute; raising the temperature to 95°C for 15 seconds. Primers with normal melting curves were selected as candidate primers. The reaction system included 2μl cDNA, 5μl 2×TB Green, 0.4μM / 0.4μM primers F / R (10μM), 0.2μl ROX reference dye II (50X), and 2.2μl ddH2O.
[0028] B7. Probe design and verification: When predicting the product sequence based on the reference primer design, the primer position is close to the primer end and does not overlap with the primer to ensure that the Taqman probe has a suitable Tm value and GC content while following the design principles. Use DNAMAN to detect mismatches between the designed probes and primers. In combined detection, pay attention to the mismatches between the two pairs of primers and the two probes, and avoid severe mismatches. Based on the results of the dye-based qPCR experiment, group genes with similar Ct values, modify the fluorescent groups that do not interfere with each other, and synthesize probes. After centrifuging the Taqman probe, the sample was dissolved in DEPC water, and a 100 μM storage solution was prepared. The following system was used (reference system - 50 μl probe and primer as an example): 1. One gene in each well: 50 μl probe and primer, 45 μl DEPC water, 2 μl F primer, 2 μl R primer and 1 μl probe; 2. Two genes in each well (50 μl probe and primer, 40 μl DEPC water, 4 μl F primer, 4 μl R primer, 2 μl probe) to prepare the primer-probe mixture. Cancer adjacent tissue cDNA was used as a template and ABI TaqPath TM ProAmp TM MasterMix and primer-probe mixture were used for qPCR amplification verification. The reaction system and procedure were as follows: reaction system (2×Taqpath 5μl, cDNA 2μl, single gene primer-probe mixture 2.5μl / dual gene primer-probe mixture 3μl, supplemented to 10μl with H2O), reaction procedure (50℃5min; 95℃5min; 10 cycles: 95℃15sec, 60℃(according to annealing temperature change)1min; 95℃5min; 40 cycles: 95℃15sec, 60℃(according to annealing temperature change)1min). The following criteria were used to determine whether the probe was suitable for subsequent detection: stable amplification in each replicate well in a single detection; the change in Ct value before and after combination was no more than 0.5; in the negative control, the amplification efficiency of individual and combined detection was not amplified or significantly lower than that of the positive detection well. Probes that met the criteria were used for subsequent sample detection.
[0029] B8. Sample detection: Multiplex qPCR detection was performed using the Taqman probe method. The preparation of the primer-probe mixture and the reaction system, as well as the reaction procedure, were the same as in B5. After detection, the Ct value of the sample was recorded. The copy number of the target gene in the sample was calculated using the standard curve method. The specific steps were as follows: Prepare synthetic standards for each gene and perform 10 4 , 10 5 , 10 6 , 10 7 , 10 8 and 10 9Use the diluted standard as a template, amplify using the validated primers and probes, and record the Ct value. Establish a standard curve by plotting the copy number of the standard versus the corresponding Ct value, derive an equation, and use the Ct value obtained in the sample test to calculate the copy number of each sample using the standard curve equation.
[0030] Preferably, the construction of a pan-cancer classification model based on characteristic molecules screened by TaqMan qPCR in step S3 specifically comprises the following steps:
[0031] C1. The blood-derived exosome TaqMan qPCR data were divided into a training set and a validation set (8:2) using a stratified random sampling method. The "log2" and "scale" functions in the R base package were used for data normalization. The "ComBat" function in the sva package was used to remove the batch effect. The caret package was used to process the data using nine machine learning algorithms. The ETR.sig was used to train the pan-cancer classification model, and a 10-fold CV hyperparameter adjustment was performed to optimize the model performance. To ensure robustness, the optimization process was repeated 10 times with different random seeds for each resampling.
[0032] C2, using five machine learning algorithms to build classification models for eight types of tumors, with sample grouping and parameter adjustment methods consistent with the above binary variable method;
[0033] C3. Train pan-cancer tumor binary classification and multi-class classification models on the training set, then apply these models to the validation cohort and systematically compare the classification effects of each model. The model with the best performance will be selected as the final pan-cancer classification model.
[0034] C4. In order to optimize the gene signatures for classifying individual tumor types and healthy controls, each tumor type was iteratively submitted to univariate logistic regression and LASSO analysis. Then, the gene signatures showing the most promising results were used to individually construct tumor classification models for eight types of blood-derived exosome TaqMan qPCR data using machine learning methods. For each specific tumor type, the classification effects of these models were thoroughly evaluated, and ROC curves were drawn using the pROC package and ggplot2 to fully demonstrate the classification performance of the models.
[0035] Preferably, the nine machine learning algorithms in step C1 include support vector machine svmRadialWeights algorithm, support vector machine svmRadial algorithm, naive Bayes NB algorithm, random forest RF algorithm, k nearest neighbor knn algorithm, AdaBoost classification tree algorithm, Boosted logistic regression algorithm, linear LASSO Ridge algorithm and gradient boosting machine Gbm algorithm.
[0036] Preferably, the five machine learning algorithms in step C2 include a multilayer perceptron (mlp) algorithm, a linear kernel support vector machine (svmLinear) algorithm, a random forest (RF) algorithm, a k-nearest neighbor (knn) algorithm, and a classification and regression tree (rpart) algorithm.
[0037] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:
[0038] A classification marker for eight common malignant tumors, which is an RNA contained in blood exosomes.
[0039] In some specific embodiments, the classification comprises distinguishing subjects with eight common malignancies from other subjects.
[0040] In some specific embodiments, the other subjects include those who are older than 18 years old and are considered asymptomatic and healthy in a health check.
[0041] In some specific embodiments, the exosome complex is obtained from blood, serum or plasma, preferably from serum.
[0042] The present invention also relates to the use of the detection reagent of the aforementioned marker in the preparation of 8 common malignant tumor detection reagents or kits.
[0043] In some specific embodiments, the detection reagent includes an exosome extraction reagent and a blood exosome RNA detection reagent.
[0044] In some specific embodiments, the detection reagent for blood exosome RNA includes upstream and downstream primers and a detection probe for PCR.
[0045] The present invention also relates to a detection reagent or a test kit prepared by the above application.
[0046] The present invention also relates to: a classification system for eight common malignant tumors, the system comprising a subject information acquisition module and a classification module, wherein:
[0047] The subject information acquisition module is used to obtain the detection information of the aforementioned markers;
[0048] The classification module is used to distinguish whether the subject suffers from one of eight common malignant tumors based on the detection information of the marker.
[0049] In some specific embodiments, if the detection information of the marker exceeds the threshold, the subject is determined to suffer from 8 common malignant tumors, otherwise the subject is determined to not suffer from 8 common malignant tumors.
[0050] In some specific embodiments, the system further includes a detection module and / or a display module.
[0051] In some specific embodiments, the detection module is used to detect the aforementioned markers. Preferably, the detection module uses the aforementioned detection reagent or kit for detection.
[0052] In some specific implementations, the display module is used to display the classification results, preferably, the classification results are displayed by display, printing or broadcasting.
[0053] Beneficial Effects
[0054] The present invention provides biomarkers, detection reagents or kits for 8 common malignant tumors and their applications. Compared with the prior art, the present invention has the following advantages: the biomarkers and detection kits for risk prediction of 8 common malignant tumors, based on the blood exosome TaqMan qPCR technology and 12 screened RNA characteristic molecules (ETR.sig), construct a pan-cancer classification and specific tumor classification model, and the model has high specificity and accuracy (see Figure 4 ). This study highlights the value of ETR.sig in detecting and localizing a variety of human cancers, and that ETR.sig can be used as a non-invasive biomarker for early pan-cancer detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] In order to more clearly illustrate the specific implementation of the present invention or the technical solution in the prior art, the following is a brief introduction to the drawings required for use in the specific implementation or the prior art description. Obviously, the drawings in the following description show some implementations of the present invention, and for ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0056] Figure 1 The overall flow chart of the construction of a pan-cancer classification model based on blood exosome RNA in the present invention;
[0057] Figure 2 This is a flowchart of the construction of a pan-cancer classification model based on blood exosome RNA sequencing in the present invention;
[0058] Figure 3 This is a flow chart for constructing a pan-cancer classification model based on blood exosome TaqMan qPCR technology in the present invention;
[0059] Figure 4 This is a graph showing the classification performance evaluation results of the pan-cancer classification model based on blood exosome TaqMan qPCR technology of the present invention. DETAILED DESCRIPTION
[0060] The embodiments of the present invention will be described in detail below in conjunction with the examples, but it will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. If no specific conditions are specified in the examples, the conditions are carried out according to normal conditions or manufacturer recommendations. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased from the market.
[0061] Example 1
[0062] The following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0063] See also Figure 1-4 The embodiment of the present invention provides a technical solution: a marker suitable for predicting the risk of 8 common malignant tumors, which is based on the blood exosome TaqMan qPCR technology and 12 screened RNA characteristic molecules ETR.sig, and can be used as a non-invasive biomarker for early pan-cancer detection.
[0064] The main purpose of this embodiment is to establish a method for quantitative detection of blood exosome RNA, the method comprising:
[0065] 1. Sample collection and processing: Fasting peripheral blood was collected. The samples were stored at 4°C and transported to the laboratory on ice. The blood samples were coagulated at room temperature for at least 30 minutes and up to 2 hours. Then, all samples were centrifuged at 1600×g for 15 minutes to separate the serum, and the supernatant was collected in a 1.5ml centrifuge tube and numbered. The serum samples were immediately frozen at -80°C until further processing.
[0066] 2. Isolation and RNA extraction of blood-derived exosomes: Blood-derived exosomes were isolated and RNA was extracted using the exoRNeasy Midi / Maxi Kit. The specific steps are as follows: Add Buffer XBP to the sample at a ratio of 1:1. Mix by inversion 5 times to ensure thorough mixing. The mixture is then added to the exoEasy spin column and centrifuged at 500×g for 1 minute. (Note: If there is residual liquid on the membrane, further centrifuge at 5000×g for 1 minute to ensure that all liquid passes completely through the membrane.) Next, add 3.5 ml of BufferXWP and centrifuge at 5000×g for 1 minute to wash the column and remove residual buffer. Discard the filtrate and bottom collection tube, and transfer the spin column to a new collection tube. Then, add 700 μl of QIAzol to the column membrane and centrifuge at 5000×g for 5 minutes to collect the lysate and then transfer it completely to a 2 ml tube. The lysate in the tube is gently mixed and incubated at room temperature (15-25°C) for 5 minutes. Then, add 90 μl of chloroform, cap the tube tightly, and mix vigorously for 15 seconds. Incubate at room temperature for 2-3 minutes. Then place the tube in a pre-refrigerated centrifuge and centrifuge at 12,000 × g for 15 minutes at 4°C. Transfer the supernatant to a new 2.0 ml tube (be careful to avoid aspirating the organic phase). Add an equal volume of ethanol and invert several times. Then, add 700 μl of the mixture to the RNeasy MinElute spin column in a 2 ml collection tube and incubate for 2 minutes, then cap the tube. Centrifuge at 12,000 × g for 1 minute at room temperature, and discard the filtrate. Repeat this step until all the mixture is used. Then, add 700 μl of Buffer RWT to the RNeasy MinElute spin column, cap the tube, centrifuge at 12,000 × g for 1 minute at room temperature, and discard the filtrate. Add 500 μl of Buffer RPE to the RNeasy MinElute spin column, cap the tube, centrifuge at 12,000 × g for 1 minute at room temperature, and discard the filtrate. Add 500 μL of Buffer RPE to the RNeasy MinElute spin column, cap the tube, centrifuge at 12,000 × g for 2 minutes at room temperature, and discard the filtrate. Place the RNeasy MinElute spin column in a new 2.0 mL collection tube, centrifuge at 12,000 × g for 5 minutes at room temperature, and discard the filtrate and the bottom 2.0 mL collection tube. Place the RNeasy MinElute spin column in a new 1.5 mL tube and add 14 μL of pre-heated RNase-free water to the center of the silica membrane. Cap the tube and centrifuge at 12,000 × g for 1 minute at room temperature. Discard the RNeasy MinElute spin column and collect the purified RNA solution in a 1.5 mL tube.For the isolated exosomes, we used different techniques for characterization, including transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and western blotting (WB).
[0067] 3. Reverse transcription of blood-derived exosome RNA: cDNA was generated by a two-step reverse transcription process, which included gDNA digestion and cDNA chain synthesis. The reaction components and procedures for each step are as follows. Step 1: gDNA digestion. In a 13μl reaction mixture, add 2.0μl of 5×gDNA Eraser buffer, 1.0μl of gDNAEraser, and 10μl of total RNA and mix gently. Perform the reaction in a PCR instrument, set the program to 42°C for 2 minutes, and then keep it at 4°C. Step 2: Perform reverse transcription. In a 20μl reaction mixture, add 13.0μl from the first step reaction mixture, 1.0μl of PrimeScript RT Enzyme Mix I, 1.0μl of RTPrimer Mix, 4.0μl of 5×PrimeScript Buffer2 (for real-time), and 1.0μl of RNase-free dH2O and mix gently. Perform the reaction in a PCR instrument, set the program to 37°C for 15 minutes, then incubate at 85°C for 5 seconds, and finally keep it at 4°C.
[0068] 4. Primer design and synthesis of detection targets: The target gene sequence was retrieved using the Ensembl database, and qPCR primers were designed using the NCBI primer design tool website (https: / / www.ncbi.nlm.nih.gov / tools / primer-blast / index.cgi?LINK_LOC=BlastHome). Primer design criteria included a melting temperature (Tm) in the range of 55-65°C, a GC content in the range of 40%-60%, a minimum number of mismatches, and good specificity.
[0069] 5. Primer verification: RNA was extracted from cancer / tumor adjacent tissues or cell lines and reverse transcribed into cDNA templates. Exosomal RNA of the sample to be verified was also prepared and reverse transcribed into cDNA. The melting temperature (Tm) value of each pair of primers was analyzed, and 3-4 gradient annealing temperature values were set. The cDNA of cancer / tumor adjacent tissues or cell lines was used as a template, and diluted primers were used as amplification primers. PCR amplification was performed at different gradient annealing temperatures (35 cycles) using TB Green II enzyme. The PCR program was as follows: pre-denaturation at 95°C for 30 seconds; denaturation at 95°C for 5 seconds; annealing at 58°C, 59°C or 60°C for 30 seconds; extension at 72°C for 15 seconds; final extension at 72°C for 5 minutes. The reaction mixture included 2μl cDNA, 5μl 2×TB Green, 0.4μM / 0.4μM primers F / R (10μM), and 2.2μl ddH2O. Mix the PCR products with DNA loading buffer and verify their size by 1.5% agarose gel electrophoresis to confirm the expected amplification product size and primer specificity and determine the optimal annealing temperature. Select primers with a single amplification product and the expected fragment size. Use cancer / tumor adjacent tissue or cell line cDNA as template and blood-derived exosome cDNA as template using TB-based Premix Ex Taq TM The melting curve of the primers was determined by qPCR of the dye. The PCR program was as follows: pre-denaturation at 95°C for 30 seconds; denaturation at 95°C for 5 seconds; annealing at the selected optimal annealing temperature for 34 seconds; raising the temperature to 95°C for 15 seconds, annealing at the selected optimal annealing temperature for 1 minute; raising the temperature to 95°C for 15 seconds. Primers with normal melting curves were selected as candidate primers. The reaction system included 2μl cDNA, 5μl 2×TB Green, 0.4μM / 0.4μM primers F / R (10μM), 0.2μl ROX reference dye II (50X), and 2.2μl ddH2O.
[0070] 6. Probe design and verification: When predicting the product sequence based on the reference primer design, the primer position is close to the primer end and does not overlap with the primer to ensure that the Taqman probe has a suitable Tm value and GC content while following the design principles. Use DNAMAN to detect mismatches between the designed probes and primers. In combined detection, pay attention to the mismatches between the two pairs of primers and the two probes, and avoid serious mismatches (see Table 1 for the primer probes for each gene lock detection). Based on the results of the dye-based qPCR experiment, genes with similar Ct values are grouped, fluorescent groups that do not interfere with each other are modified, and probes are synthesized. After centrifuging the Taqman probe, the sample is dissolved in DEPC water, and a 100 μM storage solution is prepared. Use the following system (reference system - 50 μl probe and primer as an example): 1. One gene in each well: 50 μl probe and primer, 45 μl DEPC water, 2 μl F primer, 2 μl R primer and 1 μl probe; 2. Two genes in each well (50 μl probe and primer, 40 μl DEPC water, 4 μl F primer, 4 μl R primer, 2 μl probe) to prepare primer-probe mixture. Cancer adjacent tissue cDNA was used as template and ABITaqPath TM ProAmp TM Master Mix and primer-probe mixture were used for qPCR amplification verification. The reaction system and procedure were as follows: reaction system (2×Taqpath 5μl, cDNA 2μl, single gene primer-probe mixture 2.5μl / dual gene primer-probe mixture 3μl, supplemented to 10μl with H2O), reaction procedure (50℃5min; 95℃5min; 10 cycles: 95℃15sec, 60℃(according to annealing temperature change)1min; 95℃5min; 40 cycles: 95℃15sec, 60℃(according to annealing temperature change)1min). The following criteria were used to determine whether the probe was suitable for subsequent detection: stable amplification in each replicate well in a single detection; the Ct value change before and after the combination was no more than 0.5; in the negative control, the amplification efficiency of the single and combined detection was not amplified or significantly lower than that of the positive detection well. Probes that met the criteria were used for subsequent sample detection.
[0071] 7. Sample detection: Multiplex qPCR detection was performed using the Taqman probe method. The preparation of the primer-probe mixture and reaction system, as well as the reaction procedure, were the same as before. After detection, the Ct value of the sample was recorded. The copy number of the target gene in the sample was calculated using the standard curve method.
[0072] Table 1 Primer sequences for each gene
[0073]
[0074]
[0075]
[0076] Example 2
[0077] The main purpose of this example is to evaluate the classification effect of blood exosome RNA signature molecules (ETR.sig) on 8 common malignant tumors, mainly including:
[0078] 1. Recruit 1385 subjects with confirmed clinical diagnosis results. The present invention has been approved by the Clinical Research Ethics Committee of Guangxi Medical University (approval number: GXMU2022-0154). Clinical samples were collected from the First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University Cancer Hospital, Shanghai Changhai Hospital, Suzhou Municipal Hospital, the First Affiliated Hospital of Soochow University, and Yulin First People's Hospital. Before sampling, the participants signed a written informed consent. From June 2022 to September 2023, a total of 1385 participants were recruited continuously, including individuals with breast cancer (n=128), colon adenocarcinoma (n=120), renal clear cell carcinoma (n=141), hepatocellular carcinoma (n=120), lung adenocarcinoma (n=121), ovarian cancer (n=115), pancreatic adenocarcinoma (n=111), prostate adenocarcinoma (n=143), and healthy controls (n=386). Tumor cases were confirmed by surgical pathology and examined independently by two pathologists. The inclusion criteria for patients were as follows: (1) age > 18 years; (2) clear pathological diagnosis; (3) no anticancer treatment before blood collection; (4) no other history of cancer; (6) signed informed consent. The inclusion criteria for the healthy control group were as follows: (1) age > 18 years; (2) underwent a health examination and were considered as asymptomatic and healthy. The exclusion criteria were as follows: (1) previously diagnosed with a tumor; (2) received ablation therapy; (3) had other malignant tumors.
[0079] 2. The blood exosome RNA of 1385 subjects was detected respectively (for the detection method, see Example 1).
[0080] 3. According to the diagnosis result of the subject and the copy number of blood exosome RNA, the ROC curve of the blood exosome RNA was drawn using R software.
[0081] 4. Conclusion: Based on Figure 4 From the results shown, it can be seen that the AUC of the ROC curve of the pan-cancer classification model of ETR.sig is as high as 0.915, the ROC curves of the tumor classification model Macro and Micro are both higher than 0.98, and the AUC of the single tumor classification model is greater than 0.85, indicating that the marker of the present invention has a good indicative effect on 8 common malignant tumors.
[0082] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the above embodiments, it should be understood by those skilled in the art that the technical solutions described in the above embodiments may still be modified, or some or all of the technical features therein may be replaced by equivalents. These modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A set of 8 common malignant tumor biomarkers, characterized in that: The marker is 12 RNA characteristic molecules ETR.sig obtained by RNA sequencing and TaqMan qPCR detection of exosomes in blood, including ALB, FCER1G, KRT18, LCN2, PPDPF, SLC9A3R2, AGO2, CKS2, MALAT1, RAB32, S100A9 and UBE2Q2 genes. It can be used as a non-invasive biomarker for early pan-cancer detection.
2. The 8 common malignant tumor biomarkers according to claim 1, characterized in that: The specific steps include: S1. Screening of RNA signature molecules in pan-cancer blood exosomes based on RNA sequencing; S2. Screening of RNA signature molecules in pan-cancer blood exosomes based on TaqMan qPCR; S3. Construct a pan-cancer classification model based on characteristic molecules screened by TaqMan qPCR.
3. The method for detecting markers suitable for predicting the risk of 8 common malignant tumors according to claim 2, characterized in that: The step S1 of screening RNA characteristic molecules in pan-cancer blood exosomes based on RNA sequencing specifically includes the following steps: A1. Construct a blood-derived exosome RNA sequencing (exoRNA-seq) dataset, which includes a total of 194 healthy control samples, and exoRbase=118, CNP0005119=31, CNP0002099=28, CNP0000926=17; A2, quality control of the original fastq data was performed using trim-galore, followed by STAR alignment using the reference genome hg38, sorting using SAMtools, and final gene expression quantification using featureCounts; A3. In the blood exosome RNA-seq data, we integrated 8 tumor exoRNA-seq data. Differentially expressed genes were screened using the DESeq2 software package, with a threshold of P value < 0.01 and fold change (FC) ≥ 1.4 or ≤ -1.
6. Then, univariate logistic regression analysis was used to screen genes for building classification models, and genes with P value < 0.05 were retained. In addition, LASSO analysis was used, and 1000 repeated 10-fold cross-validation CVs were performed to refine the selection of feature gene sets. A4. Use machine learning technology to select the best gene set from LASSO analysis, and use stratified random sampling method to divide the exoRNA-seq cohort into a training set and a validation set with a ratio of 7:
3. The training set is used to build a random forest RF classification model, and the validation set is used to evaluate the classification performance. The effectiveness of the model is evaluated by calculating the area under the curve (AUC) value of the receiver operating characteristic (ROC) curve. Finally, the best gene set is determined by comparing the AUC value of the model in the validation set.
4. The method for detecting markers suitable for predicting the risk of 8 common malignant tumors according to claim 3, characterized in that: In step A1, exoRbase provides samples of patients with breast cancer (BRCA, n=140), colorectal cancer (COAD, n=35), hepatocellular carcinoma (LIHC, n=112), ovarian cancer (OV, n=30) and pancreatic adenocarcinoma (PAAD, n=164). In addition, the exoRNA-seq data of lung adenocarcinoma (LUAD, n=83), renal clear cell carcinoma (KIRC, n=29) and prostate adenocarcinoma (PRAD, n=31) with access numbers CNP0005119, CNP0002099 and CNP0000926 under CNGBdb in the study.
5. The method for screening markers suitable for predicting the risk of 8 common malignant tumors according to claim 3, characterized in that: The whole process is implemented using the tidymodels and pROCR packages.
6. The method for detecting markers suitable for predicting the risk of 8 common malignant tumors according to claim 2, characterized in that: The step S2 of screening the RNA characteristic molecules in pan-cancer blood exosomes based on TaqMan qPCR specifically includes the following steps: B1. Selection of experimental participants; B2. Sample collection and processing; B3, Isolation of blood-derived exosomes and RNA extraction; B4, reverse transcription of blood-derived exosome RNA; B5, primer design and synthesis of detection targets; B6, primer verification; B7, probe design and verification; B8. Sample testing.
7. The method for detecting markers suitable for predicting the risk of 8 common malignant tumors according to claim 2, characterized in that: The construction of a pan-cancer classification model based on characteristic molecules screened by TaqMan qPCR in step S3 specifically includes the following steps: C1. The blood-derived exosome TaqMan qPCR data were divided into training set and validation set (8:2) by stratified random sampling method. The "log2" and "scale" functions in the R base package were used for data normalization. The batch effect was removed by the "ComBat" function in the sva package. The caret package was used to process nine machine learning algorithms. The pan-cancer classification model was trained using ETR.sig, and the hyperparameters of 10-fold CV were adjusted to optimize the model performance. To ensure robustness, the optimization process was repeated 10 times for each resampling using different random seeds. Finally, a two-classification pan-cancer screening model was constructed to distinguish cancer patients from healthy people. C2. Five machine learning algorithms were used to construct classification models for eight types of tumors. The sample grouping and parameter adjustment methods were consistent with the above binary classification variable method. C3. Train pan-cancer tumor binary classification and multi-class classification models on the training set, then apply these models to the validation cohort and systematically compare the classification effects of each model. The model with the best performance will be selected as the final pan-cancer classification model. C4. In order to optimize the gene signatures for classifying individual tumor types and healthy controls, each tumor type was iteratively submitted to univariate logistic regression and LASSO analysis. Then, the gene signatures showing the most promising results were used to individually construct tumor classification models for eight types of blood-derived exosome TaqMan qPCR data using machine learning methods. For each specific tumor type, the classification effects of these models were thoroughly evaluated, and ROC curves were drawn using the pROC package and ggplot2 to fully demonstrate the classification performance of the models.
8. The method for detecting markers suitable for predicting the risk of 8 common malignant tumors according to claim 7, characterized in that: The nine machine learning algorithms in step C1 include support vector machine svmRadialWeights algorithm, support vector machine svmRadial algorithm, naive Bayes NB algorithm, random forest RF algorithm, k nearest neighbor knn algorithm, AdaBoost classification tree algorithm, Boosted logistic regression algorithm, linear LASSO Ridge algorithm and gradient boosting machine Gbm algorithm.
9. The method for detecting markers suitable for predicting the risk of eight common malignant tumors according to claim 7, characterized in that: The five machine learning algorithms in step C2 include a multilayer perceptron mlp algorithm, a linear kernel support vector machine svmLinear algorithm, a random forest RF algorithm, a k nearest neighbor knn algorithm, and a classification and regression tree rpart algorithm.
Citation Information
Patent Citations
Methylation marker for early screening of generic solid tumors and application of methylation marker
CN117165689A
Identification and targeted modulation of gene signaling networks
US20210254056A1
